Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17652360 | 1.00 | ACE (0.44) | ACEREN | |
| SCHEMBL18616806 | 1.00 | ACE (0.44) | ACEREN | |
| SCHEMBL18616038 | 0.94 | ACE (0.49) | ACEREN | |
| SCHEMBL4859280 | 0.94 | ACE (0.49) | ACEREN | |
| SCHEMBL4866241 | 0.94 | ACE (0.49) | ACEREN | |
| SCHEMBL7505332 | 0.87 | ACE (0.45) | ACEREN | |
| SCHEMBL8220132 | 0.87 | ACE (0.45) | ACEREN | |
| SCHEMBL22128407 | 0.86 | SRC (0.36) | ACEREN | |
| SCHEMBL26697144 | 0.86 | SRC (0.36) | ACEREN | |
| SCHEMBL4862936 | 0.86 | SRC (0.36) | ACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844022-B1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2013-08-14 | — | — | EP | claimed |
| JP-2008525522-A | — | — | 2008-07-17 | — | — | JP | claimed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | claimed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | claimed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| US-12286491-B2 | Image forming device and image forming method | RICOH COMPANY, LTD. (JP) | 2025-04-29 | — | — | US | disclosed |
| US-20220259338-A1 | IMAGE FORMING DEVICE AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2022-08-18 | — | — | US | disclosed |
| CN-107001391-B | Boronic acid derivatives | 默克专利股份公司 | 2020-11-27 | — | — | CN | disclosed |
| US-10669289-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2020-06-02 | — | — | US | disclosed |
| EP-3201206-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-09-18 | — | — | EP | disclosed |
| EP-3201206-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-09-18 | — | — | EP | disclosed |
| CN-109280116-A | Constituent, solidfied material, image forming apparatus and image forming method | 株式会社理光 | 2019-01-29 | — | — | CN | disclosed |
| US-20180179232-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| EP-3201206-A1 | BORONIC ACID DERIVATIVES | Merck Patent GmbH (DE) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016050358-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | WO | disclosed |
| EP-1844022-B1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2013-08-14 | — | — | EP | disclosed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | disclosed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669289-B2 | Boronic acid derivatives | BCL9, BCL9L, BCL6 | ACE 2371/4885REN 3083/4885 |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ACE 1439/4885REN 474/4885 |
| US-20180179232-A1 | BORONIC ACID DERIVATIVES | BCL9, BCL9L, BCL6 | ACE 2371/4885REN 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.